GTBP

• The company was added to the Russell 2000 and Chicago Options Exchange, and has approximately $40 million to execute business plans for the next couple of years.
• Completed a sponsored research agreement with the University of Minnesota involving Dr. Jeffrey Miller's team to enhance the TriKE platform.
• The GTB-3550 TriKE clinical trial shows safety and clinical results, is well-tolerated by patients, activates NK cells, and is a monotherapy.
• Pipeline includes TriKE product candidates targeting solid tumor cancers, undergoing GMP manufacturing and preclinical evaluation.
• Greg Berk discussed the GTB-3550 Phase I trial details, including safety, biologic activity, NK cell activation, and upcoming dose escalation to the 200 microgram cohort.

• Escalation to the 200 microgram cohort in the GTB-3550 Phase I trial is planned for next week.
• Updated safety and efficacy data from the GTB-3550 Phase I trial will be presented at the ESMO conference in September.
• The Phase I trial is expected to conclude later in the fall, with final data potentially presented in winter/spring, possibly released as a press release.
• Intend to pursue Phase II with monotherapy if a compelling efficacy signal is observed, and consider combination with standard of care chemotherapy, starting with AML and venetoclax/azacitidine.

No detailed financial performance for product segments is provided in the transcript as it focuses on company progress and clinical trials rather than traditional product segment financials.

• Operate in a competitive and rapidly changing environment where new risks emerge periodically.
• Actual results may materially differ from forward-looking statements due to various uncertainties, factors, and assumptions.

Q: Can you provide color on what to expect at ESMO?

A: Greg Berk stated they will present updated safety data on up to 12 patients at ESMO in September, with patient 13 being dosed next week.

Q: Details on the Grade 1 CRS observed in the GTB-3550 trial?

A: Greg Berk said it was just fever, ruled out infection, and was not a dose limiting toxicity.

Q: Dr. Miller's involvement evolution and platform advancement?

A: Martin Schroeder said Jeff Miller's involvement will continue strongly, with a Sponsored Research Agreement to further understand TriKE's capabilities and develop new dual-targeting TriKEs.

Q: Timing of final data release from the GTB-3550 trial?

A: Greg Berk said they won't determine the MTD until later in the fall, with final data potentially in winter/spring, possibly released as a press release.

Q: Deployment of GTB-3550 in the AML treatment continuum?

A: Tony Cataldo said monotherapy is the base case initially, with potential combination with standard of care chemotherapy later, including the MRD cohort in Phase II.

Q: B7H3 targeted TriKE preclinical data and conference presentation?

A: Martin Schroeder said the B7H3 TriKE has preclinical data showing good killing in vitro and animal models, positioning as an additional therapeutic agent, with data potentially presented at conferences.

Q: ClinicalTrials.gov status for GTB-3550 and second-generation TriKEs?

A: Tony Cataldo said sites in Wisconsin were on hold and ready for Phase II; Martin Schroeder discussed second-generation TriKEs using nanobodies for improved potency and steric interaction.